Slide 1: Parsortix Liquid Biopsy Preliminary Results for the year ended 30 April 2017
Parsortix Liquid Biopsy Preliminary Results for the year ended 30 April 2017 Andrew Newland and Ian Griffiths 27 July 2017 © ANGLE plc 2017 Page 1
Slide 2: Legal disclaimer
Legal disclaimer LSE AIM: AGL OTCQX: ANPCY This presentation has been prepared by ANGLE plc (the “Company”). By attending this presentation and/or reviewing the slides you agree to be bound by the following conditions. The information and opinions contained in this presentation have not been indepen
Slide 3: Highlights
Highlights Liquid Biopsy ANGLE’s Parsortix system Simple blood test for Positive results from 400 patient Ovarian Cancer studies in personalised cancer care Europe and US Proven performance with multiple Key MD Anderson leading 400 patient Breast Cancer FDA clinical study. Opinion Leaders Analytical
Slide 4: Financial Results for the year ended April 2017 (unaudited)
Financial Results for the year ended 30 April 2017 (unaudited) Year ended 30 April 2017 2016 Statement of Comprehensive Income £’000 £’000 Revenue 498 361 Cost of sales (123) (107) Comments Gross profit 376 254 Research use sales established and Operating costs (7,810) growing (5,703) Tax credit and
Slide 5: Parsortix – the Complete Picture
ParsortixTM – the Complete Picture Intact CTCs not just ctDNA Compatible with existing downstream analysis techniques Parsortix captures living cancer cells These cannot be present unless the patient has cancer Evidence-based driven by KOLs and clinical studies Patented product solution Scaleable bu
Slide 6: Benefits of Parsortix CTCs
Benefits of Parsortix CTCs 1. CTCs are live cancer cells circulating in the blood known as circulating tumour cells 3. Tissue obtained from simple peripheral blood test 2. cfDNA also known as ctDNA is cell-free circulating fragments of DNA from dead 4. Access to CTCs technically challenging given lo
Slide 7: Far-reaching market potential
Far-reaching market potential Evidence-based approach to prove performance with ovarian cancer, FDA breast cancer Substantiating value as sample collection platform Emerging $ multi-billion market (Goldman Sachs $14bn in US alone by 2025) Partnering strategy for widespread deployment © ANGLE plc 201
Slide 8: Clinical Applications
Clinical Applications 1a 1b 2 3 Research Pilot Verification Validation Discovery Study Study Study Ovarian Cancer Triage Clinical Applications Metastatic Breast Cancer Platform Clearance Prostate Cancer Colorectal Cancer Head & Neck Cancer Lung Cancer Pancreatic Cancer © ANGLE plc 2017 Page 8
Slide 9: Ovarian cancer detection: triaging for pelvic mass surgery
Clinical application Ovarian cancer detection: triaging for pelvic mass surgery: £300 million market p.a. Detection of ovarian cancer key unmet medical need US market statistics − 750,000 women p.a. abnormal pelvic mass − >200,000 women have surgery − 10-11% have cancer Women with cancer need expens
Slide 10: Ovarian cancer clinical studies: 400 patients
Clinical application Ovarian cancer clinical studies: 400 patients 400 patient European (ANG-001) and United Moving to Optimisation and Validation Phase States (ANG-003) studies − Medical University of Vienna, Charité and Vivantes Optimisation (6 months) to improve performance − University of Roches
Slide 11: Regulatory clearance for clinical use
Regulatory clearance for clinical use Breast cancer FDA clearance progress (400 patient study) Potential to be first FDA cleared system for ANG-002 clinical study plan developed in harvesting cancer cells from blood consultation with several world-class US breast cancer centres Seeking FDA clearance
Slide 12: Breast cancer metastatic biopsy comparison
Clinical application under consideration Breast cancer metastatic biopsy comparison University of Southern California Norris Comprehensive Cancer Center CTCs harvested and RNA-Seq analysis successful for 100% of patients CTCs from Parsortix liquid biopsy had similar patterns of expression for 192 ge
Slide 13: Non-invasive metastatic breast cancer biopsy: £1 billion market potential
Clinical application under consideration Non-invasive metastatic breast cancer biopsy: £1 billion p.a. market potential Non-invasive, repeatable, lower cost, more effective ANGLE FDA study in metastatic breast cancer to investigate RNA-Seq (full next generation sequencing) in larger patient sample M
Slide 14: Non-invasive prostate biopsy using Parsortix
Clinical application under consideration Non-invasive prostate biopsy using Parsortix £3 billion p.a. market potential Barts Cancer Institute pilot studies − harvested CTCs in 100% of patients (52 patient study) − detected cancer in 100% of the metastatic prostate cancer patients and 75% early stage
Slide 15: Prostate cancer metastasis and prediction of survival
Clinical application under consideration Prostate cancer metastasis and prediction of survival Barts Cancer Institute Prostate cancer most common male cancer. 1.1 million new cases in 2012 Number of Parsortix EMTing CTCs correlated with Kaplan Meier curve metastasis 92% accuracy (81 patient study) O
Slide 16: Research use sales growing
Research use sales Research use sales growing − over 145 Parsortix instruments in active use and growing rapidly − over 30,000 blood separations have already been performed on the Parsortix system Instrument Cassette 1 Price £40,000 £100 Research use sales £250m p.a. market potential 1 Cost £12,000
Slide 17: Parsortix patented system developing a world-leading position
Parsortix patented system developing a world-leading position in emerging $ multi-billion liquid biopsy market Providing the Complete Picture (viable, intact CTCs for DNA, RNA, and protein analysis not just ctDNA) FDA study to support platform clearance for metastatic breast cancer with results expe
Slide 18: ANGLE plc
ANGLE plc ANGLE Europe Ltd ANGLE North America Inc 10 Nugent Road 3711 Market Street The Surrey Research Park University Science Center 8th floor Guildford GU2 7AF Philadelphia PA 19104 United Kingdom USA Website: www.ANGLEplc.com © ANGLE plc 2017 Page 18